This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Olanzapine Induces Insulin Resistance: Results From A Prospective Study

Christoph F. Ebenbichler, MD; Markus Laimer, MD; Ursula Eder, MD; Barbara Mangweth, PhD; Elisabeth Weiss, MD; Alex Hofer, MD; Martina Hummer, MD; Georg Kemmler, PhD; Monika Lechleitner, MD; Josef R. Patsch, MD; and W. Wolfgang Fleischhacker, MD

Published: December 15, 2003

Article Abstract

Background: The aim of this study was to compare glucose metabolism in patients with schizophrenia receiving olanzapine with that in control subjects.

Method: We conducted a prospective, controlled, open study comparing body weight, fat mass, and indices of insulin resistance/sensitivity in 10 olanzapine-treated patients with ICD-10 schizophrenia (olanzapine dose range, 7.5-20 mg/day) with those of a group of 10 mentally and physically healthy volunteers. Weight, fat mass, and indices of insulin resistance/sensitivity were assessed over individual 8-week observation periods from November 1997 to October 1999.

Results: Fasting serum glucose and fasting serum insulin increased significantly in the olanzapine-treated patients (p = .008 for glucose and p = .006 for insulin). The homeostasis model assessment (HOMA) index for beta cell function did not change significantly in the olanzapine-treated patients, whereas the HOMA index for insulin resistance did increase (p = .006). In the control group, these parameters were stable. A significant increase in body weight (p = .001) and body fat (p = .004) was seen in patients treated with olanzapine, while the control group showed no significant changes.

Conclusion: This study indicates that the disturbances in glucose homeostasis during antipsychotic treatment with olanzapine are mainly due to insulin resistance. However, beta cell function remains unaltered in olanzapine-treated patients. We conclude that treatment with some second-generation antipsychotic drugs may lead to insulin resistance.

Volume: 64

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF